Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 16,097 | 15,825 | 146,267 | 62,546 | 31,575 |
| Gross Profit | 16,097 | 15,825 | 146,267 | 62,546 | 31,575 |
| Operating Expenses | 124,427 | 118,528 | 98,102 | 104,680 | 115,405 |
| Operating Income | -108,330 | -102,703 | 48,165 | -42,134 | -83,830 |
| Interest Expense | 5,262 | 5,158 | 5,057 | 2,849 | 0 |
| Other Income | 4,602 | 4,478 | 4,568 | 3,189 | 1,673 |
| Pre-tax Income | -108,990 | -103,383 | 47,676 | -41,794 | -82,157 |
| Income Tax | 2,025 | 742 | N/A | 17 | N/A |
| Net Income Continuous | -111,015 | -104,125 | 47,676 | -41,811 | -85,942 |
| Minority Interests | -1,336 | -1,179 | -999 | -486 | N/A |
| Net Income | $-109,679 | $-102,946 | $48,675 | $-41,325 | $-85,511 |
| EPS Basic Total Ops | -1.03 | -0.96 | 0.46 | -0.39 | -0.81 |
| EPS Basic Continuous Ops | -1.04 | -0.97 | 0.45 | -0.39 | -0.81 |
| EPS Diluted Total Ops | -1.02 | -0.96 | 0.45 | -0.39 | -0.80 |
| EPS Diluted Continuous Ops | -1.03 | -0.97 | 0.44 | -0.39 | -0.80 |
| EBITDA(a) | $-105,458 | $-100,375 | $50,062 | $-38,755 | $-80,273 |